N‐acetylcysteine attenuates the development of cardiac fibrosis and remodeling in a mouse model of heart failure

Oxidative stress plays a central role in the pathogenesis of heart failure. We aimed to determine whether the antioxidant N‐acetylcysteine can attenuate cardiac fibrosis and remodeling in a mouse model of heart failure. Minipumps were implanted subcutaneously in wild‐type mice (n = 20) and mice with cardiomyopathy secondary to cardiac specific overexpression of mammalian sterile 20‐like kinase 1 (MST‐1; n = 18) to administer N‐acetylcysteine (40 mg/kg per day) or saline for a period of 8 weeks. At the end of this period, cardiac remodeling and function was assessed via echocardiography. Fibrosis, oxidative stress, and expression of collagen types I and III were quantified in heart tissues. Cardiac perivascular and interstitial fibrosis were greater by 114% and 209%, respectively, in MST‐1 compared to wild type (P ≤ 0.001). In MST‐1 mice administered N‐acetylcysteine, perivascular and interstitial fibrosis were 40% and 57% less, respectively, compared to those treated with saline (P ≤ 0. 03). Cardiac oxidative stress was 119% greater in MST‐1 than in wild type (P < 0.001) and N‐acetylcysteine attenuated oxidative stress in MST‐1 by 42% (P = 0.005). These data indicate that N‐acetylcysteine can blunt cardiac fibrosis and related remodeling in the setting of heart failure potentially by reducing oxidative stress. This study provides the basis to investigate the role of N‐acetylcysteine in chronic heart failure.

[1]  Y. Duan,et al.  N-Acetyl Cysteine improves the diabetic cardiac function: possible role of fibrosis inhibition , 2015, BMC Cardiovascular Disorders.

[2]  D. Kaye,et al.  Augmented endothelial l‐arginine transport ameliorates pressure‐overload‐induced cardiac hypertrophy , 2015, Experimental physiology.

[3]  B. C. Bernardo,et al.  Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets , 2015, Archives of Toxicology.

[4]  N. Rajapakse,et al.  Endothelial cationic amino acid transporter‐1 overexpression can prevent oxidative stress and increases in arterial pressure in response to superoxide dismutase inhibition in mice , 2014, Acta physiologica.

[5]  M. Salarifar,et al.  N-Acetylcysteine Effects on Transforming Growth Factor-β and Tumor Necrosis Factor-α Serum Levels as Pro-Fibrotic and Inflammatory Biomarkers in Patients Following ST-Segment Elevation Myocardial Infarction , 2013, Drugs in R&D.

[6]  Tevfik F Ismail,et al.  Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. , 2013, JAMA.

[7]  P. Gao,et al.  Apocynin attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction in mice , 2013, Acta Pharmacologica Sinica.

[8]  H. Shimokawa,et al.  Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. , 2012, Journal of cardiology.

[9]  L. Mulligan,et al.  Left ventricular midwall fibrosis as a predictor of mortality and morbidity after cardiac resynchronization therapy in patients with nonischemic cardiomyopathy. , 2012, Journal of the American College of Cardiology.

[10]  H. Krum,et al.  Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-β. , 2012, Cardiovascular therapeutics.

[11]  D. Kaye,et al.  CXCR4 Antagonism Attenuates the Cardiorenal Consequences of Mineralocorticoid Excess , 2011, Circulation. Heart failure.

[12]  V. Eder,et al.  Hemin decreases cardiac oxidative stress and fibrosis in a rat model of systemic hypertension via PI3K/Akt signalling. , 2011, Cardiovascular research.

[13]  Yanjie Lu,et al.  Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFβ1 expression and activation of p38‐MAPK and ERK1/2 , 2011, British journal of pharmacology.

[14]  M. Frenneaux,et al.  Antioxidant treatment for heart failure: friend or foe? , 2009, QJM : monthly journal of the Association of Physicians.

[15]  I. Efimov,et al.  Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms , 2009, Circulation.

[16]  Yao Sun,et al.  Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats , 2008, Molecular and Cellular Biochemistry.

[17]  P. Mulder,et al.  Neutral sphingomyelinase inhibition participates to the benefits of N-acetylcysteine treatment in post-myocardial infarction failing heart rats. , 2007, Journal of molecular and cellular cardiology.

[18]  Yao Sun Oxidative stress and cardiac repair/remodeling following infarction. , 2007, The American journal of the medical sciences.

[19]  R. Erbel,et al.  Bidirectional Role of Tumor Necrosis Factor-&agr; in Coronary Microembolization: Progressive Contractile Dysfunction Versus Delayed Protection Against Infarction , 2007, Circulation research.

[20]  Ajay M Shah,et al.  Oxidative stress and redox signalling in cardiac hypertrophy and heart failure , 2006, Heart.

[21]  A. Marian,et al.  Antifibrotic effects of antioxidant N-acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. , 2006, Journal of the American College of Cardiology.

[22]  P. Doevendans,et al.  Myocyte apoptosis in heart failure. , 2005, Cardiovascular research.

[23]  J. Zicha,et al.  Chronic N-Acetylcysteine Administration Prevents Development of Hypertension in Nω-Nitro-L-Arginine Methyl Ester-Treated Rats: The Role of Reactive Oxygen Species , 2005, Hypertension Research.

[24]  F. Roudot-thoraval,et al.  N-Acetylcysteine Treatment Normalizes Serum Tumor Necrosis Factor-&agr; Level and Hinders the Progression of Cardiac Injury in Hypertensive Rats , 2004, Circulation.

[25]  S. Vatner,et al.  Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. , 2003, The Journal of clinical investigation.

[26]  P. Singal,et al.  Oxidative Stress and Apoptosis in Heart Dysfunction , 2002, Herz.

[27]  P. Anversa,et al.  Oxidative Stress–Mediated Cardiac Cell Death Is a Major Determinant of Ventricular Dysfunction and Failure in Dog Dilated Cardiomyopathy , 2001, Circulation research.

[28]  A. Dart,et al.  beta(2)-adrenergic receptor overexpression exacerbates development of heart failure after aortic stenosis. , 2000, Circulation.

[29]  Per Capita,et al.  About the authors , 1995, Machine Vision and Applications.

[30]  W. H. Betts,et al.  N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction. Safety and biochemical effects. , 1995, Circulation.

[31]  J. McMurray,et al.  Evidence of oxidative stress in chronic heart failure in humans. , 1993, European heart journal.

[32]  J. Mariani,et al.  Bone marrow-derived cells contribute to fibrosis in the chronically failing heart. , 2010, The American journal of pathology.

[33]  Stefano Geuna,et al.  Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. , 2008, Endocrinology.

[34]  Hiroyuki Tsutsui,et al.  [Oxidative stress and heart failure]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.

[35]  B. Greenberg,et al.  Molecular Medicine Tumor Necrosis Factor-�–Induced AT 1 Receptor Upregulation Enhances Angiotensin II–Mediated Cardiac Fibroblast Responses That Favor Fibrosis , 2022 .